Chemotherapy is now employed in earlier-stage disease in neoadjuvant, adjuvant, and combined-modality treatments. The aim of this article is to review the current systemic treatments for NSCLC.
Elizabeth S. Waxman, RN, MSN, NP-C
Advertisement
Articles by Elizabeth S. Waxman, RN, MSN, NP-C
Hypersensitivity/infusion reactions can be caused by monoclonal antibodies and chemotherapeutic agents. Immediate interventions are often required.
Advertisement
Latest Updated Articles
An Infusion Reaction to CetuximabApril 18th 2011
Current Treatment Options for Non–Small-Cell Lung CancerAugust 27th 2012
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5